Ipsen Announces It is No Longer Eligible for the PEA-PME Scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st , 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st , 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms, and centers located in the heart of leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com .
For further information:
Ian Weatherhead, +44 (0) 7584230549
Vice-President, Corporate External communications
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Senior Manager, Global External Communications
Eugenia Litz, +44 (0) 1753 627721
Vice-President Investor Relations
Côme de La Tour du Pin, +33 (0)1 58 33 53 31
Investor Relations Manager
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
HCL-TECHNOLOGIES21.2.2019 20:08:07 | Pressemeddelelse
Recipients of HCL GRANT 2019 Felicitated by Amitabh Kant & Sourav Ganguly
FPCF/FPCC21.2.2019 18:50:03 | Pressemeddelelse
International Indigenous Languages Conference Set for June in British Columbia
AXILUM-ROBOTICS21.2.2019 18:02:10 | Pressemeddelelse
Axilum Robotics Announces U.S. FDA 510(k) Clearance for TMS-Cobot
MYPOS-EUROPE-LTD21.2.2019 15:59:13 | Pressemeddelelse
myPOS Presented with Best POS Innovation Award by the Merchant Payment Ecosystem
CREA-RECORDS21.2.2019 15:46:12 | Pressemeddelelse
New Release Crea Records: "ABBA We Love You Forever"
MA-ULTIVUE21.2.2019 15:32:11 | Pressemeddelelse
Ultivue Expands Global Presence with Opening of European Subsidiary, Ultivue EMEA Srl
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum